-
公开(公告)号:US10221217B2
公开(公告)日:2019-03-05
申请号:US14978132
申请日:2015-12-22
申请人: University of Washington, Center For Commercialization , The Scripps Research Institute , International AIDS Vaccine Initiative
IPC分类号: A61K39/00 , A61K39/21 , A61K39/12 , C07K14/005 , C07K16/10 , A61K38/00 , G01N33/564
摘要: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
-
2.
公开(公告)号:US20160185825A1
公开(公告)日:2016-06-30
申请号:US14978132
申请日:2015-12-22
申请人: University of Washington, Center For Commercialization , The Scripps Research Institute , International AIDS Vaccine Initiative
IPC分类号: C07K14/005
CPC分类号: C07K14/005 , A61K38/00 , A61K39/12 , A61K39/21 , C12N2740/16122 , C12N2740/16134 , G01N33/564
摘要: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
摘要翻译: 本发明涉及HIV gp120的工程外结构域(eOD)及其突变体及其制备和使用方法。 突变体eOD可有利于引发CD4结合位点(CD4b) - 定向广泛中和抗体(bnAb)和/或改善与成熟VRC01的结合和/或改善与种系VRC01和其他VH1-2的种系的结合 衍生的广泛中和抗体。 突变体eOD还可以包括eOD上的聚糖掩蔽突变。 本发明还包括将eOD融合到各种蛋白质多聚体以增强免疫原性,以及设计代表VRC01表位和周围环境中HIV序列的完整多样性的不同eOD的鸡尾酒。
-
公开(公告)号:US10421789B2
公开(公告)日:2019-09-24
申请号:US16291726
申请日:2019-03-04
申请人: University of Washington, Center for Commercialization , The Scripps Research Institute , International AIDS Vaccine Initiative
IPC分类号: A61K39/00 , A61K39/21 , C07K16/10 , A61K39/12 , C07K14/005 , G01N33/564 , A61K38/00
摘要: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
-
公开(公告)号:US20190194262A1
公开(公告)日:2019-06-27
申请号:US16291726
申请日:2019-03-04
申请人: University of Washington, Center For Commercialization , The Scripps Research Institute , International AIDS Vaccine Initiative
IPC分类号: C07K14/005 , A61K39/21 , A61K39/12 , A61K38/00 , G01N33/564
CPC分类号: C07K14/005 , A61K38/00 , A61K39/12 , A61K39/21 , C12N2740/16122 , C12N2740/16134 , G01N33/564
摘要: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
-
5.
公开(公告)号:US20140322269A1
公开(公告)日:2014-10-30
申请号:US14251132
申请日:2014-04-11
申请人: University of Washington , International AIDS Vaccine Initiative , The Scripps Research Institute
发明人: Po-Ssu Huang , Joseph Graham Jardine , Sergey V. Menis , William Ray Schief, JR. , Neil P. King
IPC分类号: A61K39/21 , C07K14/005
摘要: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
摘要翻译: 本发明涉及HIV gp120的工程外结构域(eOD)及其突变体及其制备和使用方法。 突变体eOD可有利于引发CD4结合位点(CD4b) - 定向广泛中和抗体(bnAb)和/或改善与成熟VRC01的结合和/或改善与种系VRC01和其他VH1-2的种系的结合 衍生的广泛中和抗体。 突变体eOD还可以包括eOD上的聚糖掩蔽突变。 本发明还包括将eOD融合到各种蛋白质多聚体以增强免疫原性以及设计代表VRC01表位和周围环境中HIV序列的完全多样性的不同eOD的鸡尾酒。
-
-
-
-